The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuxi

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer is a phase 1/2, interventional study registered as NCT07204574 by Chang Gung Memorial Hospital, with a registry enrolment figure of 40 participants, started 2025-05-14 and due to reach its primary completion in 2025-12-31. Interventions recorded: HCB101; Bevacizumab; Cetuximab (Erbitux); FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan); FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil). Conditions listed: CRC. Primary outcome: Number of subjects with MTD of HCB101 in combination with Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI; Overall Rate Response (ORR). Colorectal eligibility wording from the registry: "With histologically/cytologically confirmed diagnosis of unresectable locally advanced or metastatic colorectal cancer, with both RAS and BRAF wild-type, who have experienced treatment failure with prior chemotherapy for locally advanced or metastatic disease (intended for second-line treatment)". Sites: Taiwan. No results are recorded here; the registry entry is the source.